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Reply to the Editor:
Dr Taheri made an important point in his
comment, which we probably should have
discussed in our article. However, first I, on
behalf of my coauthors, wish to clarify that
we did not inject “isogenic myofibril
grafts,” which would represent a differen-
tiated anatomic unit of a muscle tissue.
Instead, we transplanted either skeletal
myoblasts, which are immature progenitor
cells, or marrow stromal cells, which con-
tain a pluripotent cell population. Such im-
mature cells are able to migrate and self-
assemble with preexisting supracellular
structure, as we reported.
The hypothesis we postulated to explain
the mechanism of this phenomenon should
indeed predict that those donor cells, if
implanted as an isolated island within a
scar tissue, would lack the microenviron-
ment to allow them to integrate into the
preexisting native myocardial syncytium.
We and others have pointed out that how
such cells surrounded by scar contribute to
the myocardial function, as has been re-
ported experimentally and in some early
clinical trials, remains unclear at present.1
It is of some interest to recall how the
strategy of implanting cells into scar
started. In our studies in the early 1990s,2,3
which were the first attempts to use cell
therapy for myocardial regeneration, we
lacked the tools for cell labeling and thus
created a homogeneous scar induced by
cryoinjury. By implanting myoblasts
within such a scar, we were able to show
that the new myofibers surrounded by the
scar tissue originated from our donor cells.
Because turning noncontractile scar tissue
into potentially contractile muscle tissue is
an intuitively appealing idea, many inves-
tigators in the subsequent studies, both ex-
perimental and clinical, have continued to
use the model of implanting cells within
the scar tissue, even though there has been
no convincing evidence that these isolated
muscle fibers can actually contribute to the
synchronized contractile function of the
myocardium.
In studying the pathophysiologic roles
of marrow stromal cells, it has been shown
that tissue injuries, such as myocardial in-
farction, can send a signal to recruit mar-
row stromal cells from the bone marrow,
which traffic through the bloodstream to
target the infarcted segment of the myocar-
dium. There they undergo milieu-depen-
dent differentiation, expressing a number
of phenotypes.4 We have suggested that
some of these cells that reached the peri-
infarct zone became endothelial and vascu-
lar smooth muscle cells to participate in
vasculogenesis and enhance collateral cir-
culation. Some cells, which reached the
scar tissue through patent collateral ves-
sels, may express a myofibroblastic pheno-
type and participate in scar maturation to
reduce scar expansion and rupture. The
marrow cells in the peri-infarct zone that
are in contact with viable and contracting
host myofibers may differentiate into car-
diomyocytes and integrate into the existing
myofibers as we reported1, and this may
play a role in modulating the postinfarct
remodeling process of the ventricle. Yet
other mechanisms are possible. The neo-
cardiomyocytes, which have received phe-
notypic signals from native cardiomyo-
cytes at the peri-infarct zone, may then
migrate toward the myocardial scar to re-
duce infarct size. Various transforming
growth factors and cytokines coming from
the surrounding cells and extracellular matrix
may also play important roles, as suggested
by Dr Taheri. Clearly, much needs to be
learned, and from such understanding better
clinical strategies to use cell therapy for myo-
cardial injury may yet evolve in the future.
Ray C.-J. Chiu, MD, PhD
Senior author
McGill University
Montreal, Quebec, Canada
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Asymptomatic mitral valve
incompetence: Is there evidence for
surgery?
To the Editor:
The article by David and colleagues1 in the
May 2003 issue of the Journal, “Late Out-
comes of Mitral Valve Repair for Floppy
Valves: Implications for Asymptomatic Pa-
tients,” stirs important unanswered ques-
tions and concerns. The conclusion that
patients with asymptomatic mitral valve in-
competence are candidates for surgery
might be extrapolative yet beneficial—if it
had stemmed from a different study design.
In statistical terms, significance for operat-
ing was clearly established; however, this
was more rhetorical than useful in clinical
practice. The following issues were not
mentioned in the discussion or among the
discussants.
First, asymptomatic simply means no
symptoms. Mitral valve surgery is feasible,
but its benefits to the individual patient
cannot be observed here because of the
confounding variables in the methodology
and results. To the reader, the concept of
cause and effect is paramount to executing
successful cardiovascular epidemiology.
Whereas the scientific sequence of cause
and effect is clear, the application of such a
valid concept in this article leans to the
reverse order. In other words, because sur-
gery in patients without symptoms had a
low morbidity and mortality (cause), it is
recommended to operate for asymptomatic
mitral incompetence (effect). Lowering the
threshold to operate must stem from con-
vincing data, and even if statistically sig-
nificant the clinical indication is neither
relative nor absolute. The patient’s physio-
logic status must the underlying cause for
an operation, and the outcome of the oper-
ation (effect) must treat that cause. In this
article despite the effect being feasible, the
cause is far from a true clinical indication.
The practicing surgeon can be confused
with the paradigm of cause and effect that
appears to argue that the mortality is higher
among patients with symptoms. Drawing
feasibility from such a statistic may intro-
duce a new “fuzzy logic” dimension that
has no order and no cause followed by
effect features.2 This logic results from
many decision-making and problem-solv-
ing tasks that are too complex to be under-
stood quantitatively; however, people suc-
ceed by using knowledge that is imprecise
rather than precise.
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Second, it is interesting that absolute
risk reduction in mortality from 23% to 6%
is 17% in those symptom-free patients who
were operated on. However, all variables in
a scientific study must be controlled except
the single variable that is being studied.
Thus, when David and colleagues1 at-
tempted to modify a successful operative
procedure, underlying background pathol-
ogies in the control and study groups
needed to be similar. This was lacking.
Third, the demographic data (Table1 in
the original article1) reveal an important
cause with regard to the population sample.
Atrial fibrillation (AF) was more prevalent
in the symptomatic than asymptomatic
group (P  .0001). Chronic AF carries
greater risk than intermittent AF, doubling
the risk of cardiovascular mortality. In
other words, implications for symptom-
free patients are only indirectly related, as
opposed to a direct cause-effect relation-
ship with AF.3 Moreover, diabetes mellitus
in the symptomatic group approached a
statistically significant difference (P 
.07). More recently, it has been shown that
all the patients with insulin-dependent dia-
betes mellitus with left diastolic dysfunc-
tion have evidence of definitive autonomic
neuropathy. Such isolated diastolic dys-
function may be the principal physiologic
mechanism in these patients. The annual
mortality from diastolic heart failure varies
widely, from 9% to 28%,4 This variable
should be addressed in the context of pa-
tient cohort by reviewing echocardio-
graphic evidence of diastolic dysfunction.
The mortality rate among patients with di-
astolic heart failure is 4 times that among
persons without heart failure but half that
among patients with systolic heart failure.
Third, apart from the semantics of
asymptomatic, of more interest at mean
follow-up 93% of patients in the asymp-
tomatic group were in New York Heart
Association (NYHA) functional class I or
II, which was not statistically significant
from the symptomatic group (88%). This
result argues that mitral valve surgery re-
pair on symptom-free patients does not
confer any further clinical benefit. This sta-
tistic is consistent with others and follows
classic teachings. Also, the discrepancy be-
tween the reoperation rate and the inci-
dence of significant mitral valve regurgita-
tion indicates that not all patients having
important valve incompetence late after re-
pair undergo surgery again within the time
frame. This repeated observation creates a
new argument that recurrent mitral incom-
petence lacks substance as an indication for
operation and argues against the primary
hypothesis and conclusion of David and
colleagues.1
Fourth, David and colleagues1 did not
mention the well-known limitations to the
simple NYHA scale for cardiovascular dis-
ability. NYHA has a tendency to oversim-
plify an issue or a problem by ignoring
complexities or complications. The criteria
committee of the NYHA has provided a
widely used classification that relates
symptoms to “ordinary” activity. The term
ordinary is subject to various interpreta-
tions, as are terms such as undue fatigue.
Such terms have limited the accuracy and
reproducibility of the NYHA classification.5
In the end, it is desirable to seek patients
who need an operation. Offering such sur-
gery to symptom-free patients on the basis
of effect rather than cause, however, is
simplistic and fuzzy. Better data analytic
methodology and study design are needed
to qualify for a new indication.
Jeffrey H. Shuhaiber, MD
Department of Surgery
University of Illinois at Chicago
Chicago, IL 60612
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Reply to the Editor:
Dr Shuhaiber makes some valid points
about our study,1 but many of his com-
ments are irrelevant. He ignored the fact
that ours was an observational study and
did not establish causation but rather an
association between functional class and
late mortality after mitral valve repair for
mitral regurgitation caused by prolapse.
The objectives of the study were clearly
defined, and in addition to showing the late
outcomes of mitral valve repair for floppy
valves it also showed associations between
certain preoperative variables and late mor-
tality by multivariable analysis with boot-
strap validation. Our study was not a pro-
spective randomized trial, and consequently
we could not control the variables before the
operation as he suggested. This is, of course,
a major limitation of all retrospective studies.
One can only adjust for those factors that
were measured. Residual confounding by un-
measured variables may potentially distort
results. However, numerous studies have
shown that careful, multivariable analysis of
observational data produces treatment effects
very similar to those of randomized con-
trolled trials.2-4
Atrial fibrillation and diabetes were in-
cluded in all multivariable models. Dr Shu-
haiber’s concerns regarding chronic atrial
fibrillation may in fact provide further ar-
gument to operate on symptom-free pa-
tients. Atrial fibrillation may be a conse-
quence of deterioration in ventricular
function in patients with mitral regurgita-
tion, and by the time it first occurs irrevers-
ible changes may already be present.
His remarks regarding postoperative
functional class and the probability of re-
current mitral regurgitation in our patients
are incorrect. One would not expect symp-
tom-free patients to have lessened symp-
toms after the operation simply because
they were already in functional classes 1
and 2 (ceiling effect). The analysis at fol-
low-up was designed to demonstrate the
improvement in the patients with symp-
toms. The mechanism of mitral valve pro-
lapse was similar in both groups of pa-
tients, and recurrent mitral regurgitation
after mitral valve repair is more dependent
on the pathology of the mitral valve than on
presence or absence of preoperative symp-
toms. That is reason why recurrent mitral
regurgitation and reoperation rates were
similar in the two groups.
We agree that functional class is a soft,
subjective variable, especially between
classes 2 and 3, but certainly not between
classes 1 and 3 or 2 and 4. Moreover,
symptoms are usually the reason a patient
seeks medical advice. What our study
showed is that postponing surgery until
symptoms are more obvious (functional
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